A Study of ASP3082 in Adults With Advanced Solid Tumors
for Solid Tumor
24 locations incl. Duarte
Sponsor: Astellas Pharma Inc
Sex: All·Age: 18+
Code: NCT05382559·Phase 1·Recruiting·Listed May 2022
Next Oncology
Clinical research site in San Antonio, Texas · 22151 BULVERDE RD STE 106, SAN ANTONIO, TX 78259-1850 · (281) 783-8162
Part of NEXT Oncology
As of July 2026, 59 paid clinical trials are recruiting at Next Oncology in San Antonio, Texas. Active studies at this site cover conditions such as Advanced Solid Tumor, Advanced Solid Tumors and Colorectal Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Next Oncology (59)
A Study of TAK-505 in Adults With Solid Tumors
for Malignant Solid Tumors
15 locations incl. Orange
Sponsor: Takeda
Sex: All·Age: 18+
Code: NCT07436728·Phase 1, Phase 2·Recruiting·Listed Feb 2026
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
for KRAS Altered Advanced or Metastatic Solid Tumors
10 locations incl. Duarte
Sponsor: Amgen
Sex: All·Age: 18+
Code: NCT07094113·Phase 1·Recruiting·Listed Jul 2025
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
for Advanced Solid Tumor
8 locations incl. Denver
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT06120283·Phase 1·Recruiting·Listed Nov 2023
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
for Advanced Solid Tumor
15 locations incl. Birmingham
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06997029·Phase 1·Recruiting·Listed May 2025
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
for Non-Small Cell Lung Cancer
20 locations incl. Duarte
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT05005403·Phase 1·Recruiting·Listed Aug 2021
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
for Non-small Cell Lung Cancer (NSCLC)
21 locations incl. Orange
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT05379985·Phase 1, Phase 2·Recruiting·Listed May 2022
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
for Non-Small Cell Lung Cancer
16 locations incl. Los Angeles
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Sex: All·Age: 18+
Code: NCT06917079·Phase 1·Recruiting·Listed Apr 2025
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
for Advanced/Metastatic Solid Tumors
21 locations incl. Duarte
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07090499·Phase 1·Recruiting·Listed Jul 2025
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
for Melanoma
11 locations incl. Los Angeles
Sponsor: Regeneron Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06413680·Phase 1, Phase 2·Recruiting·Listed May 2024
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
for Locally Advanced or Metastatic ER+ HER2- Breast Cancer
21 locations incl. Los Angeles
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT04606446·Phase 2·Recruiting·Listed Oct 2020
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
for KRAS G12C Mutation
11 locations incl. Phoenix
Sponsor: Kumquat Biosciences Inc.
Sex: All·Age: 18+
Code: NCT06720987·Phase 1·Recruiting·Listed Dec 2024
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
for Specific Advanced Solid Tumors
15 locations incl. Phoenix
Sponsor: Acrivon Therapeutics
Sex: All·Age: 18+
Code: NCT06667141·Phase 1·Recruiting·Listed Oct 2024
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
for Solid Tumor Malignancies
15 locations incl. Phoenix
Sponsor: Kumquat Biosciences Inc.
Sex: All·Age: 18+
Code: NCT06994806·Phase 1·Recruiting·Listed May 2025
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
for Advanced or Metastatic Solid Tumors
10 locations incl. Scottsdale
Sponsor: Incendia Therapeutics
Sex: All·Age: 18+
Code: NCT05753722·Phase 1·Recruiting·Listed Mar 2023
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
for Advanced Solid Tumor
9 locations incl. La Jolla
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT05007782·Phase 1·Recruiting·Listed Aug 2021
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
for Ovarian Cancer
13 locations incl. Newport Beach
Sponsor: NextCure, Inc.
Sex: All·Age: 18+
Code: NCT06774963·Phase 1·Recruiting·Listed Jan 2025
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
for Advanced Solid Tumor
10 locations incl. Sarasota
Sponsor: Circle Pharma
Sex: All·Age: 12+
Code: NCT06577987·Phase 1·Recruiting·Listed Aug 2024
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
for Advanced or Metastatic Solid Tumors
3 locations incl. Denver
Sponsor: SHY Therapeutics
Sex: All·Age: 18+
Code: NCT07705334·Phase 1·Recruiting·Listed Jul 15, 2026
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
for Locally Advanced (Unresectable) or Metastatic Solid Tumors
8 locations incl. New York
Sponsor: NEOK Bio, Inc.
Sex: All·Age: 18+
Code: NCT07612189·Phase 1·Recruiting·Listed May 28, 2026
A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
for Locally Advanced (Unresectable) or Metastatic Solid Tumors
8 locations incl. New York
Sponsor: NEOK Bio, Inc.
Sex: All·Age: 18+
Code: NCT07612176·Phase 1·Recruiting·Listed May 28, 2026
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
for Advanced Cancer
3 locations incl. Dallas
Sponsor: United Immunity, co., Ltd.
Sex: All·Age: 18+
Code: NCT07605962·Phase 1, Phase 2·Recruiting·Listed May 26, 2026
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
for Malignant Neoplasm
1 location in San Antonio
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07600749·Phase 1·Recruiting·Listed May 2026
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
for Advanced Solid Tumors
6 locations incl. Norwich
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT07397338·Phase 1, Phase 2·Recruiting·Listed Feb 2026
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
for Breast Cancer
8 locations incl. Los Angeles
Sponsor: Boundless Bio, Inc.
Sex: All·Age: 18+
Code: NCT07408089·Phase 1·Recruiting·Listed Feb 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
for Colorectal Cancer
8 locations incl. Duarte
Sponsor: Cartography Biosciences
Sex: All·Age: 18+
Code: NCT07321106·Phase 1·Recruiting·Listed Jan 2026
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
for TP53 Y220C Mutation
5 locations incl. Denver
Sponsor: PMV Pharmaceuticals, Inc
Sex: All·Age: 18+
Code: NCT07372625·Phase 1·Recruiting·Listed Jan 2026
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
for Metastatic Castration-resistant Prostate Cancer
9 locations incl. La Jolla
Sponsor: Daiichi Sankyo
Sex: Male·Age: 18+
Code: NCT07244341·Phase 1·Recruiting·Listed Nov 2025
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
for Locally Advanced Solid Tumor
6 locations incl. New Haven
Sponsor: Ipsen
Sex: All·Age: 18+
Code: NCT07213817·Phase 1, Phase 2·Recruiting·Listed Oct 2025
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
for Advanced Solid Malignancies
4 locations incl. Baltimore
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07223047·Phase 1, Phase 2·Recruiting·Listed Oct 2025
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
for Advanced Solid Tumor
3 locations incl. New Haven
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All·Age: 18+
Code: NCT07166601·Phase 1·Recruiting·Listed Sep 2025
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
for Solid Tumors
3 locations incl. Houston
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT07181681·Phase 1·Recruiting·Listed Sep 2025
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
for Advanced Solid Tumors
1 location in San Antonio
Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.
Sex: All·Age: 18+
Code: NCT07060989·Phase 1, Phase 2·Recruiting·Listed Jul 2025
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
for Advanced Solid Tumors
6 locations incl. Sarasota
Sponsor: Accent Therapeutics
Sex: All·Age: 18+
Code: NCT06799065·Phase 1·Recruiting·Listed Jan 2025
BTM-3566 in Advanced Solid Tumors
for Advanced Solid Tumors
2 locations incl. Houston
Sponsor: Bantam Pharmaceuticals
Sex: All·Age: 18+
Code: NCT07266285·Phase 1·Recruiting·Listed Dec 2025
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
for Advanced Solid Tumor
5 locations incl. Celebration
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT06803680·Phase 1·Recruiting·Listed Jan 2025
Study of STP938 (Dencatistat) in Advanced Solid Tumours
for Solid Tumor
3 locations incl. St. Petersburg
Sponsor: Step Pharma, SAS
Sex: All·Age: 18+
Code: NCT06297525·Phase 1·Recruiting·Listed Mar 2024
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
for Colorectal Cancer
4 locations incl. Providence
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All·Age: 18+
Code: NCT05464030·Phase 1·Recruiting·Listed Jul 2022
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
for Participants With Advanced Solid Tumor Malignancies
5 locations incl. Grand Rapids
Sponsor: VelaVigo Bio Inc
Sex: All·Age: 18+
Code: NCT07136779·Phase 1, Phase 2·Recruiting·Listed Aug 2025
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
for Advanced or Metastatic Solid Tumor
6 locations incl. Newark
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT04617522·Phase 1·Recruiting·Listed Nov 2020
Showing the 40 most relevant of 59 recruiting trials at this site. Browse all with filters →
More research sites in San Antonio
- University of Texas Health Science Center at San Antonio (85 trials)
- Children's Hospital of San Antonio (32 trials)
- Methodist Children's Hospital of South Texas (24 trials)
- START San Antonio (22 trials)
- The University of Texas Health Science Center at San Antonio (21 trials)
- UT Health San Antonio (16 trials)
- GSK Investigational Site (13 trials)
- Texas Dermatology and Laser Specialists (13 trials)
- Texas Oncology - San Antonio (12 trials)
- Brooke Army Medical Center (11 trials)
Explore more
Paid clinical trials in San Antonio, TX · Texas clinical trials